<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">7600130</journal-id>
<journal-id journal-id-type="pubmed-jr-id">5844</journal-id>
<journal-id journal-id-type="nlm-ta">Neurosci Lett</journal-id>
<journal-id journal-id-type="iso-abbrev">Neurosci. Lett.</journal-id>
<journal-title-group>
<journal-title>Neuroscience letters</journal-title>
</journal-title-group>
<issn pub-type="ppub">0304-3940</issn>
<issn pub-type="epub">1872-7972</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30075287</article-id>
<article-id pub-id-type="pmc">6339829</article-id>
<article-id pub-id-type="doi">10.1016/j.neulet.2018.07.038</article-id>
<article-id pub-id-type="manuscript">NIHMS1503885</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>PET Imaging of Synaptic Density: A New Tool for Investigation of Neuropsychiatric Diseases</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Cai</surname>
<given-names>Zhengxin</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Li</surname>
<given-names>Songye</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Matuskey</surname>
<given-names>David</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Nabulsi</surname>
<given-names>Nabeel</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Huang</surname>
<given-names>Yiyun</given-names>
</name>
</contrib>
<aff id="A1">PET Center, Department of Radiology and Biomedical Imaging, Yale University, New Haven, CT 06520, USA</aff>
</contrib-group>
<pub-date pub-type="nihms-submitted">
<day>15</day>
<month>8</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>31</day>
<month>7</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="ppub">
<day>19</day>
<month>1</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>19</day>
<month>1</month>
<year>2020</year>
</pub-date>
<volume>691</volume>
<fpage>44</fpage>
<lpage>50</lpage>
<!--elocation-id from pubmed: 10.1016/j.neulet.2018.07.038-->
<abstract id="ABS1">
<p id="P1">The synaptic vesicle glycoprotein 2A (SV2A) is one of three isoforms of the synaptic vesicle glycoprotein 2. SV2A is expressed ubiquitously in neurons of the central nervous system, and is the binding target of the anti-epileptic drug levetiracetam. Because of the availability of positron emission tomography (PET) ligands targeting SV2A, recently there is increasing enthusiasm using SV2A PET in the study of a variety of neuropsychiatric diseases. This review discusses the recent development of radioligands for PET imaging of SV2A and its potential use in a variety of neuropsychiatric diseases.</p>
</abstract>
<kwd-group>
<kwd>SV2A</kwd>
<kwd>PET</kwd>
<kwd>synaptic density</kwd>
<kwd>Alzheimer’s disease</kwd>
<kwd>Parkinson’s disease</kwd>
<kwd>epilepsy</kwd>
<kwd>stroke</kwd>
<kwd>multiple sclerosis</kwd>
<kwd>Huntington’s disease</kwd>
<kwd>autism spectrum disorder</kwd>
<kwd>depression</kwd>
<kwd>schizophrenia</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>